-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar Biosciences Phase 2b CLOVER WaM 12-Month Data Shows 83.6% ORR And Durable Responses Exceeding 18 Months In Post-BTKi Patients

Benzinga·05/05/2026 11:11:05
Listen to the news
  • 83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months
  • FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26
  • Compelling efficacy observed in post-BTKi patients, including ~64% MRR and durable responses exceeding 18 months
  • Recently Announced Oversubscribed Financing of up to $140 Million with Leading Healthcare Institutional Investors Supports Confirmatory Study and NDA Filing for Accelerated Approval of Iopofosine I 131 in Waldenström Macroglobulinemia with the FDA